Nuevolution maintains guidance despite million-dollar loss
BY KEVIN GRØNNEMANN
Sales stood still during the first half of Nuevolution’s staggered financial year. It resulted in a loss of DKK 46 million. However, the CEO assures that the company is still going strong. “That’s biotech,” he says.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.